You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel strategy to block AAV neutralizing anitbody activity

    SBC: NABGEN INC            Topic: NIAID

    Adeno-associated virus (AAV) vectors have been successfully applied in clinical trials in patients with blindness, neurological/muscular disorders and bleeding diseases. Two AAV based gene therapy drugs have been recently approved by the FDA, Luxturna has been valued at $850,000 for a one-time treatment for a rare form of blindness and Zolgensma at $2,100,000 for spinal muscle atrophy. Gene therap ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Nucleic acid-based formulation of cytomegalovirus-vectored HIV vaccines

    SBC: TENDEL THERAPIES INC            Topic: NIAID

    This grant is for translational development of a scalable, nucleic acid-based formulation of cytomegalovirus-vectored vaccines that can be distributed without a cold chain. HIV candidate vaccines that use cytomegalovirus (CMV) as delivery vector and immunomodulatory adjuvant have shown extraordinary promise. In our preliminary work, for example, a rhesus cytomegalovirus-vectored SIV vaccine lackin ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Patterned, Responsive Cellular Therapies Using Novel Mammalian Cellular Regulator Systems

    SBC: General Biologics, Inc.            Topic: HR001119S003516

    We propose to design, build and test genetic circuits and DNA constructs that will be expressed in human cells and that will ultimately have applications for the health of warfighters. The circuits will have physiological inputs representing, for example, (1) infection/sepsis, (2) altitude sickness or blood loss, and (3) radiation exposure; which will be mediated through signal transduction pathwa ...

    STTR Phase I 2020 Department of DefenseDefense Advanced Research Projects Agency
  4. Personalized anesthetic brain monitoring:Developing novel systems, sensors, and algorithms for aging, dementia, and Alzheimers disease patients

    SBC: PASCALL Systems, Incorporated            Topic: R

    PROJECT SUMMARY In the United States, nearly 100,000 patients receive general anesthesia and sedation daily to safely undergo surgical and non-surgical procedures. A high proportion of these patients are older than 65 years of age. These older patients are at higher risk of post-operative delirium and cognitive dysfunction. Many of these older patients have dementia, including mild cognitive impai ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Pharmacological chaperones for the treatment of Open-Angle Glaucoma

    SBC: Viewpoint Therapeutics, Inc.            Topic: NEI

    Open-angle glaucoma is the second leading cause of blindness worldwide, affecting nearly 70 million individuals. Nonsynonymous mutations in the myocilin gene lead to the most common hereditary form of open-angle glaucoma and account for 3-4% of all cases. Disease-causing mutations, localized to its olfactomedin domain (mOLF), destabilize the myocilin protein, leading to its misfolding and accumula ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Preventing liver fibrosis in alcoholic hepatitis by enhancing liver regenerative capacity via transient telomere extension using lipid nanoparticle-encapsulated TERT mRNA

    SBC: REJUVENATION TECHNOLOGIES INC            Topic: 400

    Abstract Rejuvenation Technologies Inc. (RTI) aims to prevent liver fibrosis in alcoholic hepatitis (AH) by enhancing liver regenerative capacity. AH is an acute form of alcoholic liver disease with mortality of up to 50% within 1 month of presentation. Most AH patients exhibit advanced fibrosis/cirrhosis, which contributes to acute-on-chronic liver failure. RTI will ameliorate/prevent this fibros ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Prevention of corneal transplant rejection using AAV-HLA-G combination therapy

    SBC: Bedrock Therapeutics, Inc.            Topic: NEI

    Contact PD/PI: GILGER, BRIAN C Abstract Corneal blindness is a leading cause of global blindness, with allogeneic corneal transplantation (CT) being the most common form of tissue transplantation worldwide. Though approximately 180,000 CT surgeries are carried out each year, around 12.7 million are currently awaiting a donor cornea to undergo the operation. Still, CT surgery is accompanied by a hi ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Q-GRFT Enema Development Supporting a Multi-Administration Clinical Study

    SBC: GROW BIOMEDICINE LLC            Topic: NIAID

    Project Summary Unprotected receptive anal intercourse (RAI) is the sexual behavior with the highest per-act risk of HIV acquisition, conferring 10 to 20 times more risk than unprotected vaginal intercourse. We are developing an antiviral rectal rinse (enema) using a novel HIV entry inhibitor, the lectin Griffithsin (GRFT), because there is a lack of on-demand antiviral HIV prevention products tha ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Recombinant Fc fusions for treatment of uropathogenic E. coli

    SBC: Planet Biotechnology Incorporated            Topic: 300

    Urinary tract infections (UTIs) are among the most common bacterial infections, affecting 150 million people worldwide each year. In the USA, community-acquired UTIs account for about 11 million cases each year that cost the U.S. public health budget $5 billion annually. Uropathogenic Escherichia coli (UPEC) accounts for up to 80% of UTIs. While UTIs are currently treated with antibiotics, the fre ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Reversal of Tau Pathology with MSUT2 siRNA Conjugates

    SBC: DTx Pharma, Inc.            Topic: NIA

    Project Summary Genetic and pathologic evidence in andapos;pureandapos; tauopathies such as Progressive Supranuclear Palsy (PSP), Corticobasilar Degeneration (CBD) and some cases of Fronto-temporal Dementia (FTD) directly implicate tau as causing neuronal cell death, while in Alzheimer’s Disease (AD) tau accumulation correlates with development and progression of cognitive impairment. Because of ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government